NEO Stock Forecast 2025-2026
Distance to NEO Price Targets
NEO Price Momentum
10 Quality Stocks Worth Considering Now
Researching NeoGenomics (NEO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NEO and similar high-potential opportunities.
Latest NEO Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, NEO has a bullish consensus with a median price target of $18.00 (ranging from $12.00 to $26.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $10.09, the median forecast implies a 78.4% upside. This outlook is supported by 10 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Alex Nowark at Craig-Hallum, projecting a 157.7% upside. Conversely, the most conservative target is provided by Andrew Cooper at Raymond James, suggesting a 18.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NEO Analyst Ratings
NEO Price Target Range
Latest NEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NEO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $15.00 |
| Feb 26, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $18.00 |
| Feb 19, 2025 | B of A Securities | Derik De Bruin | Neutral | Maintains | $16.00 |
| Feb 19, 2025 | Needham | Mike Matson | Buy | Maintains | $18.00 |
| Jan 28, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $18.00 |
| Jan 16, 2025 | Benchmark | Bruce Jackson | Hold | Reiterates | $0.00 |
| Jan 15, 2025 | Needham | Mike Matson | Buy | Reiterates | $19.00 |
| Jan 13, 2025 | Benchmark | Bruce Jackson | Hold | Downgrade | $0.00 |
| Jan 10, 2025 | Needham | Mike Matson | Buy | Reiterates | $19.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Neutral | Maintains | $19.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Initiates | $22.00 |
| Nov 6, 2024 | Needham | Mike Matson | Buy | Reiterates | $19.00 |
| Sep 25, 2024 | Needham | Mike Matson | Buy | Reiterates | $19.00 |
| Sep 24, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $18.00 |
| Jul 30, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $18.00 |
| Jul 30, 2024 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $19.00 |
| Jul 30, 2024 | Needham | Mike Matson | Buy | Reiterates | $19.00 |
| May 2, 2024 | BTIG | Mark Massaro | Buy | Maintains | $21.00 |
| May 1, 2024 | Craig-Hallum | Alex Nowark | Buy | Assumes | $26.00 |
| May 1, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $18.00 |
NeoGenomics Inc. (NEO) Competitors
The following stocks are similar to NeoGenomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NeoGenomics Inc. (NEO) Financial Data
NeoGenomics Inc. has a market capitalization of $1.27B with a P/E ratio of -16.2x. The company generates $660.57M in trailing twelve-month revenue with a -11.9% profit margin.
Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of -9.2% and return on equity of -8.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
NeoGenomics Inc. (NEO) Business Model
About NeoGenomics Inc.
Provides cancer diagnostics and genetic testing services.
NeoGenomics generates revenue by offering a wide range of diagnostic services that assist healthcare providers in accurately diagnosing cancer and personalizing treatment plans. Its client base includes oncologists, hospitals, and pharmaceutical companies, which drives demand for its comprehensive genomic profiling and genetic testing solutions.
Headquartered in Fort Myers, Florida, NeoGenomics is focused on innovation and research, aiming to enhance cancer treatment and advance personalized medicine. The company is well-positioned in the growing oncology market, catering to the increasing demand for precision diagnostics.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,200
CEO
Mr. Anthony P. Zook
Country
United States
IPO Year
2004
Website
www.neogenomics.comNeoGenomics Inc. (NEO) Latest News & Analysis
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Latest News
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2 days agoNeoGenomics (NEO) is not expected to meet key criteria for a potential earnings beat in its upcoming report. Investors should prepare for this outcome.
NeoGenomics may underperform in its upcoming earnings report, indicating potential stock price decline and impacting investor sentiment and decision-making.
NeoGenomics has validated its PanTracer LBx™ assay, which will be showcased alongside five other abstracts at the AACR Annual Meeting in 2025.
NeoGenomics' analytical validation of the PanTracer LBx™ assay could enhance its market position, attract investment, and influence stock performance in the biotech sector.
NeoGenomics will release its Q1 2025 financial results on April 29, 2025, before U.S. markets open.
NeoGenomics' Q1 2025 financial results announcement timing may influence stock performance, affecting investor sentiment and trading strategies ahead of market opening.
NeoGenomics Completes Acquisition of Pathline
17 days agoNeoGenomics has finalized its acquisition of Pathline, LLC, a certified laboratory based in New Jersey, enhancing its service capabilities.
NeoGenomics' acquisition of Pathline enhances its lab capabilities, potentially boosting revenue and market position in the diagnostic sector, which may impact investor sentiment and stock performance.
NeoGenomics has appointed Tony Zook as the new Chief Executive Officer, effective immediately.
Leadership changes can impact company strategy and performance. Investors may react to Zook's vision and track record, influencing stock prices and future growth potential.
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
1 month agoNeoGenomics has acquired Pathline, LLC, a certified laboratory based in New Jersey, enhancing its operational capabilities in the diagnostics sector.
NeoGenomics' acquisition of Pathline enhances its laboratory capabilities, potentially increasing market share and revenue, signaling growth prospects that could positively impact stock performance.
Frequently Asked Questions About NEO Stock
What is NeoGenomics Inc.'s (NEO) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, NeoGenomics Inc. (NEO) has a median price target of $18.00. The highest price target is $26.00 and the lowest is $12.00.
Is NEO stock a good investment in 2025?
According to current analyst ratings, NEO has 10 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NEO stock?
Wall Street analysts predict NEO stock could reach $18.00 in the next 12 months. This represents a 78.4% increase from the current price of $10.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NeoGenomics Inc.'s business model?
NeoGenomics generates revenue by offering a wide range of diagnostic services that assist healthcare providers in accurately diagnosing cancer and personalizing treatment plans. Its client base includes oncologists, hospitals, and pharmaceutical companies, which drives demand for its comprehensive genomic profiling and genetic testing solutions.
What is the highest forecasted price for NEO NeoGenomics Inc.?
The highest price target for NEO is $26.00 from Alex Nowark at Craig-Hallum, which represents a 157.7% increase from the current price of $10.09.
What is the lowest forecasted price for NEO NeoGenomics Inc.?
The lowest price target for NEO is $12.00 from Andrew Cooper at Raymond James, which represents a 18.9% increase from the current price of $10.09.
What is the overall NEO consensus from analysts for NeoGenomics Inc.?
The overall analyst consensus for NEO is bullish. Out of 16 Wall Street analysts, 10 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are NEO stock price projections?
Stock price projections, including those for NeoGenomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.